Open AccessThe Use of IV Vasoactive Intestinal Peptide (Aviptadil) in Patients With Critical COVID-19 Respiratory Failure: Results of a 60-Day Randomized Controlled Trial*
Author(s) -
J.G. Youssef,
Philip T. Lavin,
David Schoenfeld,
Richard A. Lee,
Rainer Lenhardt,
David J. Park,
Javier Pérez Fernández,
Melvin L. Morganroth,
Jonathan C. Javitt,
Dushyantha Jayaweera
Publication year - 2022
Publication title -
critical care medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.002
H-Index - 271
eISSN - 1530-0293
pISSN - 0090-3493
DOI - 10.1097/ccm.0000000000005660
Subject(s) - medicine , placebo , clinical endpoint , respiratory failure , mechanical ventilation , randomized controlled trial , odds ratio , respiratory distress , anesthesia , gastroenterology , pathology , alternative medicine